ACT Genomics is awarded the best immunotherapy solution provider in 2nd China & America Precision Medicine Forum 2018 for its research achievements in immunotherapy. ACT Genomics CSO Dr. Shu-Jen Chen will deliver a talk to elaborate on the role and application of precision medicine in immunotherapy, and discuss how to evaluate the use of immune check point inhibitor based on TMB and MSI calculation. http://www.cdmc.org.cn/2018/pmf/